We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Research results published in the BMJ suggest that post-marketing studies funded by drug companies may be too small to detect rare side effects, as reported in Yahoo!Finance.
The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the US, and two pain management products, which are currently under development